{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:36:09Z","timestamp":1747172169290,"version":"3.40.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.vph.2015.08.001","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T06:45:14Z","timestamp":1438757114000},"page":"8-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-6010","authenticated-orcid":false,"given":"Marco","family":"Zimarino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Radico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen Dalby","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.08.001_bb0005","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","article-title":"Platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine","volume":"332","author":"Lefkovits","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.08.001_bb0010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.08.001_bb0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0735-1097(99)00635-X","article-title":"Effect of glycoprotein IIb\/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction","volume":"35","author":"Neumann","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2015.08.001_bb0025","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.08.001_bb0030","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.08.001_bb0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jacc.2003.07.017","article-title":"A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction","volume":"42","author":"Antoniucci","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2015.08.001_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FJC.0b013e3181565e26","article-title":"Facilitated PCI: rationale, current evidence, open questions, and future directions","volume":"51","author":"Zimarino","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2015.08.001_bb0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH11-07-0468","article-title":"Contemporary use of glycoprotein IIb\/IIIa inhibitors","volume":"107","author":"Kristensen","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2015.08.001_bb0050","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2015.08.001_bb0055","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","article-title":"Facilitated PCI in patients with ST-elevation myocardial infarction","volume":"358","author":"Ellis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.08.001_bb0060","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","article-title":"Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial","volume":"119","author":"Mehilli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.08.001_bb0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial","volume":"372","author":"Van't Hof","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.08.001_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.107.747642","volume":"118","author":"Thiele","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.08.001_bb0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11239-006-9000-0","article-title":"Rationale for intracoronary administration of abciximab","volume":"23","author":"Romagnoli","year":"2007","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.vph.2015.08.001_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00392-011-0372-6","article-title":"Platelet inhibition and GP IIb\/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction","volume":"101","author":"Desch","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.vph.2015.08.001_bb0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.ATV.21.1.142","article-title":"Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis","volume":"21","author":"Collet","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2015.08.001_bb0090","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.V83.4.1006.1006","article-title":"Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb\u2013IIIa","volume":"83","author":"Cox","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.vph.2015.08.001_bb0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.atherosclerosis.2009.03.011","article-title":"Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention \u2014 effects on soluble CD40 ligand concentrations","volume":"206","author":"Dominguez-Rodriguez","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2015.08.001_bb0100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jcin.2010.05.017","article-title":"Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes","volume":"3","author":"Prati","year":"2010","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"10.1016\/j.vph.2015.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1001\/jama.2012.421","article-title":"Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial","volume":"307","author":"Stone","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.08.001_bb0110","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2459\/JCM.0b013e3283586fee","article-title":"Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCTAIL II study","volume":"14","author":"Prati","year":"2013","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.vph.2015.08.001_bb0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(11)61872-2","article-title":"Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial","volume":"379","author":"Thiele","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.08.001_bb0120","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ijcard.2012.12.003","article-title":"Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials","volume":"168","author":"De Rosa","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2015.08.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2015.06.001","article-title":"Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","author":"Piccolo","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2015.08.001_bb0130","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.08.001_bb0135","article-title":"Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: a meta-analysis of randomized and observational studies","author":"Zimarino","year":"2015","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.vph.2015.08.001_bb0140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","journal-title":"J. Am. Coll. Cardiol. Intv."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T21:57:09Z","timestamp":1599429429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115001779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":28,"alternative-id":["S1537189115001779"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.08.001","relation":{},"ISSN":["1537-1891"],"issn-type":[{"type":"print","value":"1537-1891"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.06.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}